Compare DexCom, Inc. (DXCM) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Orion Office REIT Inc — how do they compare? DexCom, Inc. trades at $90.68 (market cap $33.79B), while Orion Office REIT Inc trades at $2.8 (market cap $158.01M). The key difference: DexCom, Inc. is far larger — about 213.8× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | ONL | |
|---|---|---|
Market Cap | $33.79B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $89.53 | $3.04 |
52-Week Low | $54.84 | $1.93 |
Enterprise Value | $33.24B | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
ONL trades at $2.76, up 0.36% today, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $0.42 versus -$0.07 expected, but maintains negative net income and ROE. Revenue has declined from $208M in 2022 to $148M in 2025, with a net loss of -$139M. Analyst consensus is split evenly between Buy and Hold.
The outlook remains challenged by persistent losses and declining revenue, though the low P/B of 0.25 suggests asset value. Key risks include high debt and weak profitability. Upside depends on successful portfolio repositioning and a return to sustained earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
